Endovascular Treatment of Descending Thoracic Aortic Pathology: Results of the Regis-TEVAR Study

Espada, C. López; Palomino, J.P. Linares; González, José Manuel; Ortega, Elena Iborra; Lozano-Vilardell, P.; Valldaura, T. Solanich; Pérez, G. Volo; Cañibano, Estrella Blanco; Salgado, Andrés Álvarez; Fernández, Juan Carlos Fernández; Rydings, M. Hernando; Hernández, Manuel Miralles

doi:10.1016/j.avsg.2020.02.012

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recommendations for a closer postoperative follow-up program are based on detected perioperative risk factors for disease progression, particularly for AAS. 8,27,28 This analysis highlights that in the GREAT registry, DTAA, and AAS patients, once subjected to a relatively high mortality rate during re-intervention within 30 days after TEVAR, experience different outcomes among define time periods: DTAA patients have a low aorta-related mortality and re-intervention rate, although a higher all-cause mortality rate is present until 3 years after TEVAR. Conversely, the AAS group experienced a higher mortality and re-intervention rate within 1 year after TEVAR, and at 3 years these outcomes were lower when compared with those patients described in the DTAA cohort.…”

Section: Discussionmentioning

confidence: 94%

Differences in Mid-Term Outcomes Between Patients Undergoing Thoracic Endovascular Aortic Repair for Aneurysm or Acute Aortic Syndromes: Report From the Global Registry for Endovascular Aortic Treatment

et al. 2021

View full text Add to dashboard Cite

Purpose: To analyze differences in baseline characteristics, overall mortality, device-related mortality, and re-intervention rates in patients who underwent thoracic endovascular aortic repair (TEVAR) for descending thoracic aortic aneurysm (DTAA) with atherosclerotic/degenerative cause or acute aortic syndrome (AAS), using the Global Registry For Endovascular Aortic Treatment (GREAT). Materials and Methods: Patients submitted to TEVAR for AAS or DTAA, included in GREAT, were eligible for this analysis. Primary outcome was 30-day all-cause mortality rate. Secondary outcomes were 30-day aorta-related mortality and re-intervention rate, 1-year and 3-year all-cause mortality, aorta-related mortality and re-intervention rate. Results: Five-hundred and seventy-five patients were analyzed (305 DTAA and 270 AAS). Thirty-day mortality rate was 1.3% and 1.8% for DTAA and AAS, respectively (p=0.741). One-year and 3-year mortality rates were 6.2% versus 9.3 and 17.3% versus 15.9% for DTAA and AAS, respectively (p=0.209 and p=0.655, respectively). Aorta-related mortality rates at 30 days, 1 year and 3 years were 1.3%, 1.3%, and 2.6% for DTAA, 1.8%, 4.2%, and 4.2% for AAS (p=ns). Re-intervention rates at 30 days, 1 year, and 3 years were 1.3%, 4.3%, and 7.5% for DTAA, 3.3%, 8.1%, and 10.7% for AAS (p=ns). Furthermore, a specific analysis with similar outcomes was performed dividing follow-up in 3 periods (1-30 days, 31-365 days, 366-1096 days) and describing mutual differences between 2 groups and temporal trends in each group. Conclusion Patients who underwent TEVAR for DTAA or AAS experienced different mortality and re-intervention rates among years during mid-term follow-up. Although all-cause related deaths within 30 days were TEVAR-related, aorta-related deaths were more common for AAS patients within 1 year. A greater re-intervention rate was described for AAS patients, although only 1 year after TEVAR.

show abstract

Section: Discussionmentioning

confidence: 94%

Differences in Mid-Term Outcomes Between Patients Undergoing Thoracic Endovascular Aortic Repair for Aneurysm or Acute Aortic Syndromes: Report From the Global Registry for Endovascular Aortic Treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Conversely Dufour et al showed that aortic aneurysms were the most complicated and were affected by highest mortality rates probably due to the evolution of the atherosclerotic disease [12]. In the Regis-TEVAR Study, the survival at 4 year for aneurysm pathology treated with TEVAR was 65±5% [13].…”

Section: Discussionmentioning

confidence: 97%

Long-Term Outcomes and Risk Factors Analysis for Patients Undergoing Thoracic Endovascular Aorta Repair (TEVAR), According to the Aortic Pathologies

Gallo¹,

Berg²,

Torre³

et al. 2023

Annals of Vascular Surgery

View full text Add to dashboard Cite

“…Descending thoracic aorta and thoracoabdominal AA can be repaired via TEVAR or open surgery [ 71 ] . Both procedures can be performed with similar operative outcomes, acceptable morbidity and mortality, and with low rates of postoperative complications [ 73 , 74 ] . Arnaoutakis et al [ 71 ] reports TEVAR to have decreased 30-day mortality and fewer major adverse events compared with open surgery.…”

Section: Management Of Thoracic Arterial Disease In Current Eramentioning

confidence: 99%

The Aortic Pathologies: How Far We Understand It and Its Implications on Thoracic Aortic Surgery

Harky

Sokal

Hasan

et al. 2020

Braz J Cardiovasc Surg

View full text Add to dashboard Cite

Thoracic aortic diseases contribute to a major part of cardiac surgeries. The severity of pathologies varies significantly from emergency and life-threatening to conservatively managed conditions. Life-threatening conditions include type A aortic dissection and rupture. Aortic aneurysm is an example of a conservatively managed condition. Pathologies that affect the arterial wall can have a profound impact on the presentation of such cases. Several risk factors have been identified that increase the risk of emergency presentations such as connective tissue disease, hypertension, and vasculitis. The understanding of aortic pathologies is essential to improve management and clinical outcomes.

show abstract

Endovascular Treatment of Descending Thoracic Aortic Pathology: Results of the Regis-TEVAR Study

Cited by 3 publications

References 30 publications

Differences in Mid-Term Outcomes Between Patients Undergoing Thoracic Endovascular Aortic Repair for Aneurysm or Acute Aortic Syndromes: Report From the Global Registry for Endovascular Aortic Treatment

Differences in Mid-Term Outcomes Between Patients Undergoing Thoracic Endovascular Aortic Repair for Aneurysm or Acute Aortic Syndromes: Report From the Global Registry for Endovascular Aortic Treatment

Long-Term Outcomes and Risk Factors Analysis for Patients Undergoing Thoracic Endovascular Aorta Repair (TEVAR), According to the Aortic Pathologies

The Aortic Pathologies: How Far We Understand It and Its Implications on Thoracic Aortic Surgery

Contact Info

Product

Resources

About